MA5-15793

antibody from Invitrogen Antibodies

Targeting: SMAD5 Dwfc, JV5-1, MADH5

Western blot (Supportive data in Antibodypedia)

ELISA (Recommended by provider)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-15793

Provider

Invitrogen Antibodies

Product name

SMAD5 Monoclonal Antibody (3H9)

Antibody type

Monoclonal

Antigen

Purifed from natural sources

Description

MA5-15793 targets SMAD5 in indirect ELISA, FACS, IF, IHC, and WB applications and shows reactivity with Human and Rat samples. The MA5-15793 immunogen is purified recombinant fragment of human SMAD5 expressed in E. Coli. MA5-15793 detects SMAD5 which has a predicted molecular weight of approximately 52kDa.

Reactivity

Human, Rat

Host

Mouse

Isotype

IgG

Antibody clone number

3H9

Vial size

100 µL

Concentration

Conc. Not Determined

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma.

Aminuddin A, Ng PY, Leong CO, Chua EW
Scientific reports 2020 May 12;10(1):7885

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of SMAD5 using SMAD5 monoclonal antibody (Product # MA5-15793) in HeLa (1), SK-N-SH (2), PC-12 (3), Jurkat (4), and K562 (5) cell lysate.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of SMAD5 using SMAD5 monoclonal antibody (Product # MA5-15793) in HeLa (1), SK-N-SH (2), PC-12 (3), Jurkat (4), and K562 (5) cell lysate.

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of NTERA-2 cells using SMAD5 monoclonal antibody (Product # MA5-15793) (Green). Blue: DRAQ5 fluorescent DNA dye. Red: actin filaments have been labeled with phalloidin.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of NTERA-2 cells using SMAD5 monoclonal antibody (Product # MA5-15793) (Green). Blue: DRAQ5 fluorescent DNA dye. Red: actin filaments have been labeled with phalloidin.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical analysis of paraffin-embedded brain tissues (left) and lung cancer tissues (right) using SMAD5 monoclonal antibody (Product # MA5-15793) followed with DAB staining.

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometric analysis of Jurkat cells using SMAD5 monoclonal antibody (Product # MA5-15793) (green) and negative control (purple).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 Derivation of cancer stem cells (CSCs) from OSCC cell lines via a sphere-forming assay and the characterization of their stem cell-like features. ( a ) The morphology of the parental SAS and H103 and their derived tumour spheres. SAS and H103 in normal culture media were observed as polygonal squamous epithelial cells with the adherent growth pattern. Within 7 d, tumour spheres, comprised of aggregated and suspended cells derived from SAS and H103, were formed in the specialized serum-free medium containing serum substitute, heparin, and growth factors and in a low attachment plate (100x magnification). The average diameters of the SAS and H103 tumour spheres were 133.4 +- 34.36 um and 68.1 +- 13.37 um, respectively. ( b ) Assessment of cell viability of SAS, SAS tumour spheres, and H103 after 72 h exposure to cisplatin. IC 50 was defined as the concentration of cisplatin required to reduce cell viability by half. Higher IC 50 values indicated lower sensitivity of the cells towards cisplatin and possibly cisplatin resistance. ( c ) Western blots of Sox2, Oct4 and beta-actin and the relative expression levels of the Sox2 and Oct4 transcription factors normalized to the beta-actin protein in SAS and SAS tumour spheres. The full-length blots are presented in Supplementary Figure S2 . ( d ) Expression of CD338, CD117 and CD44 surface markers in both SAS and SAS tumour spheres, as analyzed by flow cytometry. Multi-staining flow cytometry was used to analyse the surface ex